KIR3DL1 and neoplasm: Similarly, amongst patients that received rituximab maintenance, those that are Group-1 (KIR2DL2+/C2+ and KIR3DL1+/Bw4+) showed improved TTRF, duration of response and tumor shrinkage than those that are Group-2 (not KIR2DL2+/C2+ and KIR3DL1+/Bw4+).